Zacks Investment Research downgraded Proteostasis Therapeutics Inc (NASDAQ:PTI) to Sell in a report released today.
- Updated: September 17, 2016
Showing a price of $18.16, Proteostasis Therapeutics Inc (NASDAQ:PTI) traded 0.55% higher on the day. The last stock close is up 4.18% relative to the two hundred day moving average, compared to the S&P 500 which has fallen -0.01% over the same time. The company has recorded a 50-day average of $13.99 and 200-day moving average of $12.36. 254,397 shares of the stock traded, up from ann average trading volume of 171,692
Zacks Investment Research has downgraded Proteostasis Therapeutics Inc(NASDAQ:PTI) to Sell in a report released 8/18/2016.
On 3/07/2016, RBC Capital Markets released a statement about Proteostasis Therapeutics Inc(NASDAQ:PTI) bumped the target price from $0.00 to $20.00 that suggested an upside of 2.18%.
With a market capitalization of $0.0, Proteostasis Therapeutics Inc has a 52 week low of $5.27 and a 52 week high of $20.63 with a P/E ratio of 0.
Brief Synopsis On Proteostasis Therapeutics Inc (NASDAQ:PTI)
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, and Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.